Research Use Only. KIRhub outputs are computational research artifacts. They are not validated for clinical decision-making, diagnosis, or treatment.

← Cohorts · bladder-landscape@3

DRR168530

—

03259d0a-e6f0-59f2-9f19-190c60514525

Score in workbench →

Clinical attributes

From the source cohort, normalized into canonical keys plus the project's native columns.

cancer_type
—
cancer_type_detailed
—
subtype
—
sex
Male

GSVA pathway preview (50 Hallmark scores)

MeasuredDerivedReference

Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.

Top 10 elevated

  • G2M_CHECKPOINT+0.440
  • E2F_TARGETS+0.420
  • ALLOGRAFT_REJECTION+0.300
  • PI3K_AKT_MTOR_SIGNALING+0.280
  • MITOTIC_SPINDLE+0.270
  • ANDROGEN_RESPONSE+0.250
  • COMPLEMENT+0.230
  • IL6_JAK_STAT3_SIGNALING+0.220
  • ESTROGEN_RESPONSE_LATE+0.210
  • GLYCOLYSIS+0.180

Top 10 suppressed

  • ANGIOGENESIS-0.210
  • MYC_TARGETS_V2-0.210
  • UV_RESPONSE_UP-0.210
  • OXIDATIVE_PHOSPHORYLATION-0.200
  • PANCREAS_BETA_CELLS-0.200
  • UNFOLDED_PROTEIN_RESPONSE-0.170
  • TGF_BETA_SIGNALING-0.120
  • EPITHELIAL_MESENCHYMAL_TRANSITION-0.100
  • TNFA_SIGNALING_VIA_NFKB-0.100
  • INTERFERON_ALPHA_RESPONSE-0.090

Patient twins — nearest pathway neighbors

MeasuredDerived

10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.

8 twins match this tumor's tissue · 2 come from a different tissue of origin

#SampleCancer typeSubtypecos similarity
1TCGA-CR-6481-01A-11R-1873-07
head-neck@1
——0.681
2TCGA-BA-4077-01B-01R-1436-07
head-neck@1
——0.628
3TCGA-CR-6471-01A-11R-1873-07
head-neck@1
——0.622
4MDT-AP-2876
medullo-epn-umap@date-based
MedMedulloblastoma0.618
5TCGA-E2-A159-01A-11R-A115-07
breast-umap@18
—C0.593
6TCGA-GC-A3I6-01A-11R-A20F-07
bladder-landscape@3
——0.593
7MDT-AP-3055
medullo-epn-umap@date-based
MedMedulloblastoma0.586
80801726c-9faf-4905-8cd9-71ad4fc3df25
colon-landscapes@1
——0.585
9SRR23036886
head-neck@1
——0.580
10TCGA-C8-A275-01A-21R-A16F-07
breast-umap@18
—C0.579

Per-pathway drug coverage

ModeledCalibratedDerived

For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.

0 of 33 elevated pathways have at least one drug that meaningfully reverses them.

Pathway (elevated)tumor scoreBest drugreversal magnitude
G2M_CHECKPOINT0.440Inavolisib— uncovered
E2F_TARGETS0.420Inavolisib— uncovered
ALLOGRAFT_REJECTION0.300Idelalisib— uncovered
PI3K_AKT_MTOR_SIGNALING0.280Inavolisib— uncovered
MITOTIC_SPINDLE0.270Inavolisib— uncovered
ANDROGEN_RESPONSE0.250Inavolisib— uncovered
COMPLEMENT0.230Inavolisib— uncovered
IL6_JAK_STAT3_SIGNALING0.220Inavolisib— uncovered
ESTROGEN_RESPONSE_LATE0.210Idelalisib— uncovered
GLYCOLYSIS0.180Inavolisib— uncovered
PEROXISOME0.170Idelalisib— uncovered
ESTROGEN_RESPONSE_EARLY0.160Inavolisib— uncovered
INFLAMMATORY_RESPONSE0.150Idelalisib— uncovered
COAGULATION0.140Binimetinib— uncovered
P53_PATHWAY0.140Idelalisib— uncovered
KRAS_SIGNALING_DN0.130Remibrutinib— uncovered
SPERMATOGENESIS0.120Inavolisib— uncovered
MTORC1_SIGNALING0.110Inavolisib— uncovered
PROTEIN_SECRETION0.110Remibrutinib— uncovered
UV_RESPONSE_DN0.110Inavolisib— uncovered